Omeros | OMER - Operating Expenses


Omeros reported $59.16M in Operating Expenses for its fiscal quarter ending in June of 2024.





Operating Expenses Change Date
Adma Biologics USD 76.41M 6.8M Dec/2025
Alnylam Pharmaceuticals USD 898.54M 66.78M Mar/2026
BioMarin Pharmaceutical USD 636.56M 39.61M Mar/2026
Cytokinetics USD 196.12M 27.43M Dec/2025
Gilead Sciences USD 4.96B 707M Dec/2025
Heron Therapeutics USD 40.55M 1.46M Dec/2025
Immunic USD 23.33M 2.67M Dec/2025
Insmed USD 513.55M 109.86M Dec/2025
Knight Therapeutics CAD 126.9M 8.29M Dec/2025
MacroGenics USD 53.32M 13.68M Dec/2025
Omeros USD 59.16M 20.13M Jun/2024
Pacira USD 172.75M 20.93M Mar/2026
Pfizer USD 90.1B 77.19B Mar/2026
Rockwell Medical USD 30.41M 1.11M Jun/2025
Sangamo BioSciences USD 33.87M 12.89M Jun/2024
Sarepta Therapeutics USD 853.02M 390.78M Dec/2025
United Therapeutics USD 804.8M 5.79B Dec/2025
Vertex Pharmaceuticals USD 1.85B 78.6M Mar/2026
Xoma USD 22.84M 1.67M Sep/2024